Celyad announces the appointment of Dr. Jean-Pierre Latere as Head of the Regenerative Medicine and Medical Device Franchise

Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the appointment of Dr. Jean-Pierre Latere as Head of the Regenerative Medicine and Medical Device Franchise, effective January 4th , 2016.

Jean-Pierre started his career as a Research Associate at the Michigan State University in the US. Following that assignment, he moved to the Johnson & Johnson group where he held various positions, from Scientist to Senior Scientist. He then joined Cardio3 BioSciences in 2008 as Project Manager Delivery System and left the company in 2012 in the position of Senior Director Business Development. Prior to joining Celyad, Jean-Pierre served as Beauty Care and Healthcare Market Global Leader at Dow Corning.

Jean-Pierre holds a PhD in Chemistry from the University of Liège, Belgium.

Dr. Christian Homsy, CEO of Celyad: "We are pleased to welcome back Jean-Pierre to our team. Jean-Pierre brings over significant experience in medical devices as well as in business and strategic development. His remit going forward will be to build and lead our Regenerative Medicine and Medical Device Franchise, and ensure we are strategically and competitively positioned in the marketplace. This newly created role signals further steps towards our ambition to grow into a truly international and recognized biotech company".

Jean-Pierre Latere: "I am very thrilled to come back to Celyad and join a seasoned team. This company is uniquely positioned to bring life changing treatments to patients. We intent to mature our portfolio and establish Celyad as a solid globally recognized company". 

Jean-Pierre Latere will be based in Mont-Saint-Guibert, Belgium and will report directly to Christian Homsy, Chief Executive Officer. 

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.